ANTI-PDL1 ANTIBODY AND USE THEREOF

Abstract

The present disclosure relates to the field of biomedicine, and more particularly, to an anti-PD-L1 antibody or antigen binding fragment and use thereof. The anti-PD-L1 antibody or antigen binding fragment according to the present disclosure includes a CDR selected from at least one of the following sequences or amino acid sequences having at least 80% identity thereto: heavy chain variable region CDR sequences: SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; or light chain variable region CDR sequences: SEQ ID NO: 4, WAS, or SEQ ID NO: 5. The antibody has a high binding affinity to PD-L1, and the present disclosure also provides a CD3 and PD-L1 bispecific antibody that has a stronger binding to tumor cells and promotes T cells to exert anti-cancer function.

CPC Classifications